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Abstract Antibodies against citrullinated proteins are
highly specific for rheumatoid arthritis (RA) and are cur-
rently used as a diagnostic marker. In this study, we wanted
to quantify the numbers of T cells that react to a wide range
of citrullinated proteins in a wide range of HLA-DR sub-
types in order to investigate whether citrullination might
create T-cell neo-epitopes and could initiate a universal
T-cell response. Therefore, PBMCs from healthy volun-
teers and RA patients were stimulated with a citrullinated
and non-citrullinated cell extract on IFNc-ELISpot. We
found a significantly higher number of IFNc-secreting cells
after stimulation with citrullinated proteins compared to
non-citrullinated proteins in RA patients (1:14,441 cells vs.
1:32,880 cells) as well as in healthy subjects (1:6,261
reactive cells compared to 1:16,212 cells). Additionally, a
higher number of IL17-secreting cells were found after
stimulation with citrullinated proteins compared to their
non-citrullinated counterparts. Our data indicate that cit-
rulline-dependent T-cell response is not restricted to RA
patients but that citrullination as such gives rise to a uni-
versal break in tolerance.
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Reactivity against citrullinated proteins is an important part
of the rheumatoid arthritis (RA) pathology, and the pres-
ence of antibodies against citrullinated proteins (ACPA)
predisposes for a more severe disease course [1]. Since
ACPA are class-switched antibodies, a citrulline-specific T
cell is likely involved in their production [2].
Several papers investigated the presence of citrulline
reactive T cells. Recently, Snir et al. detected citrulli-
nated vimentin aa 59-78-reactive T cells in both RA
patients and healthy volunteers by means of HLA-
DRB1*0401 tetramers. Moreover, similar percentages of
DR0401-positive cit-vimentin aa 59-78 cells were
observed in RA patients and controls samples [3]. James
et al. tested several citrullinated peptides for their bind-
ing capacity to HLA-DRB1*1001 [4]. The choice of
peptides for these assays was based on prediction models
for the binding to HLA-DRB1*1001, similar to Snir
et al. [3] where choice was based on potential binding to
HLA-DRB1*0401. However, the authors remarked that
peptides from prediction models might not be naturally
processed and presented and that it is likely that other
epitopes are present among the peptides that were not
studied [4].
Another recent study by Feitsma et al. investigated
reactivity against two peptides from citrullinated vimentin
and proved that these could be naturally processed [5].
They found that 3 of the 10 RA patients showed higher
IFNc response on citrullinated peptides compared to their
non-citrullinated counterpart, while no significant differ-
ence was found in healthy controls. The main disadvantage
of this study is the use of only 2 vimentin peptides and the
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selection of HLA-DRB1*04-positive patients and controls,
further restricting the reactivity under investigation.
Therefore, the need emerged for an experiment that used
a broad range of citrullinated proteins. In fact, it is possible
that while the epitopes tested in the above-mentioned
papers do not have a differential amount of reactive T cells,
other epitopes might. To circumvent the problem of T cell
assays that use a limited amount of peptides, we chose to
use whole citrullinated proteins for the stimulation of
PBMCs, which also indicates the involvement of antigen-
presenting cells and therefore mimics the situation in the
body regarding antigen processing more accurately.
Additionally, to the authors’ knowledge, the number of
reactive T cells that react to citrullinated epitopes has never
been quantified before.
An additional downside of the use of peptides and pre-
diction models is their restriction to certain HLA types.
The above-mentioned papers restrict their analyses to
HLA-DRB1*1001 [4] or HLA-DRB1*0401 [3, 5], but
other HLA types are associated with ACPA such as HLA-
DRB1*0101 and 0404 (7). Therefore, patients with a broad
range of HLA subtypes should be used in an experiment on
the T cell reactivity to citrullinated proteins (Table 1).
This study is the first to quantify the number of T
cells reactive to a broad range of non-citrullinated and in
vitro citrullinated proteins from a human cell lysate in
patients and healthy controls with different HLA-DRB1
subtypes.
In order to accurately count the low numbers of citrul-
line reactive T cells, we used IFNc-ELISpot (Mabtech)
(20 lg of non-citrullinated or citrullinated proteins per
500,000 PBMCs). In both RA patients and healthy con-
trols, a statistically significant higher number of reactive
PBMCs was found after stimulation with citrullinated
proteins compared to their non-citrullinated counterpart
(Fig. 1 upper panel). Our healthy subjects (n = 19) had on
average 1:6,261 PBMCs reactive to citrullinated proteins,
while 1:16,212 PBMCs on average was reactive against the
non-citrullinated proteins. In the RA group (n = 10), on
the other hand, an average of 1:14,441 cells and 1:32,880
cells was found to be reactive upon stimulation with cit-
rullinated and non-citrullinated proteins, respectively. The
number of spot-forming counts after stimulation with cit-
rullinated proteins was significantly increased compared to
stimulation with their non-citrullinated counterpart in both
healthy volunteers and RA patients.
Besides making the distinction between RA patients and
healthy subjects, it might be relevant to differentiate
between ACPA? and ACPA-. Our data reveal no sig-
nificant difference between ACPA? and ACPA-:
ACPA? (n = 5) and ACPA- (n = 5) patients showed a
respective average frequency of 1:16,484 and 1:12,397
reactive cells after stimulation with citrullinated proteins
and 1:34,247 and 1:31,513 after stimulation with their non-
citrullinated counterparts.
The observed T cell reactivity nearly disappeared (drop
of[96 % in reactivity for stimulation with citrullinated as
well as non-citrullinated proteins) when PBMCs were
depleted for HLA-DR, indicating that APCs are crucial for
the anticitrulline response. However, as mentioned before,
several subtypes of this HLA can be involved in this
response.
Additionally, we analysed spot-forming counts for
synovial fluid mononuclear cells from 4 RA patients.
Although the sampled population was small, we could see a
greater IFNc response after stimulation with citrullinated
proteins compared to non-citrullinated proteins (1:3,846
and 1:5,249, respectively). Overall, there were more reac-
tive T cells in synovial fluid than in peripheral blood of RA
patients, which confirmed the findings made by Ro¨nnelid
et al. [6].
Besides IFNc production, we also analysed IL17 pro-
duction of healthy and RA PBMCs by means of IL17-
ELISpot. The number of IL17-secreting cells after stimu-
lation with citrullinated proteins and non-citrullinated
proteins was rather low. Healthy subjects (n = 8) had on
average 1:160,000 reactive T cells after stimulation with
citrullinated proteins and 1:315,706 after stimulation with
non-citrullinated proteins. RA patients (n = 9) had on
average 1:177,585 reactive cells after stimulation with
citrullinated proteins and an average of less than 1 reactive
cell per 500,000 PBMCs after stimulation with non-cit-
rullinated proteins. No statistical analysis was performed,
due to the low spot count. However, a trend towards a
higher frequency of IL17-secreting cells after stimulation
with citrullinated proteins was detected (Fig. 1, lower
panel). These data are in agreement with the results
obtained by Snir et al. [3], who could also detect a trend
towards a higher frequency of IL17-secreting cells after
stimulation with a citrullinated vimentin peptide loaded on
MHC tetramer, but no significant difference. Additionally,
it should be noted that our analysis used a broader range
of proteins on a diverse HLA background, while Snir
et al. only used one peptide on a certain HLA subtype
as stimulant (citrullinated vimentin aa 59-78 on HLA-
DRB1*0401) [3].
In conclusion, several groups have recently reported T
cell reactivity against citrullinated synthetic peptides or
recombinant proteins in healthy individuals [3, 7] and RA
patients [5, 8]. All these studies restricted their experiments
to stimulation of lymphocytes of a certain HLA-DRB1
subtype with a limited amount of citrullinated synthetic
peptides or recombinant proteins and will therefore only
detect reactivity in susceptible individuals with the right
HLA type and for the specifically studied peptide(s) or
proteins. Our study is the first to quantify and characterize
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the whole citrulline reactive T cell pool independent of
HLA-DR background. We could not detect any differences
in number of citrulline reactive T cells when comparing
healthy and RA PBMC. This implies that the presence of T
cells with citrulline specificity alone is not sufficient for
RA pathology and confirms the existing presumption that
citrulline reactive T cells escape thymic selection [2].
We did, however, detect a significant difference in
spot-forming count between IFNc production after stim-
ulation of PBMC with citrullinated and non-citrullinated
proteins for both healthy volunteers and RA patients,
likely because we did not confine our study to a single cit-
rullinated peptide. This confirms the presence of autoreac-
tive T cells against citrullinated epitopes in healthy
Table 1 Patient information and clinical data: the rheumatoid factor (U/ml) and CCP (U/ml) titre and HLA-DRB1 status of the different RA
patients and healthy volunteers used throughout the study
Patient n Gender Age RF (U/ml) CCP (U/ml) HLA DRB1
Healthy controls
1 F 22 ND ND 01/08
2 F 45 \7.9 0.3 01/04
3 F 32 \7.9 0.4 04/13
4 M 37 \7.9 0.4 13/15
5 M 32 \7.9 0.4 01/07
6 F 45 \7.9 1.4 04/11
7 F 45 \10.6 0.4 11/11
8 F 24 ND ND 07/14
9 F 28 ND ND 03/09
10 M 26 ND ND ND
11 M 63 \10.6 1.1 11/13
12 F 26 ND ND ND
13 F 30 ND ND ND
14 F 61 \10.6 1 04/15
15 F 62 \10.6 1.6 07/15
16 M 60 \10.6 0.6 01/04
17 M 61 \10.6 1.6 11/15
18 F 60 \10.6 0.2 13/15
19 F 83 \10.6 1.2 01/13
RA CCP?
1 F 68 105 75 04/15
2 M 63 13.3 55 01/16
3 M 67 100 199 03/15
4 F 63 66.8 83 01/04
5 F 72 30.8 75 04/04
6 F 81 \10.6 [Max 01/03
7 F 65 156 611 04/04
RA CCP-
1 M 67 \7.9 0.4 03/07
2 M 73 \7.9 0.6 01/15
3 M 67 \7.9 0.5 01/07
4 F 68 \7.9 1.1 04/04
5 M 62 \7.9 0.5 13/16
6 F 46 \7.9 0 07/11
7 F 60 40.4 0.2 ND
ND not determined
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individuals and suggests that citrullination of proteins cre-
ates neo-epitopes that escape thymic selection during T-cell
maturation.
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Fig. 1 IFNc and IL17-reactivity of PBMCs from RA patients and
healthy controls after stimulation with non-citrullinated (non cit) and
citrullinated (cit) proteins. Top panel IFNc spot-forming counts of
500,000 PBMCs of healthy volunteers (n = 19) and RA patients
(n = 10). A significantly higher amount of spots could be counted
after stimulation with citrullinated proteins for both groups. Bottom
panel IL17 spot-forming counts of 500,000 PBMCs of healthy
volunteers (n = 8) and RA patients (n = 9). No statistical analysis
was performed due to low spot counts, but a trend towards higher
frequency of IL17-secreting cells after stimulation with citrullinated
proteins was detected
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